Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
US8063240B2 · kind B2 · utility
0Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2008 |
| Grant date | Nov 22, 2011 |
| Priority date | — |
| Expiry date | Mar 20, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.